Desvenlafaxine Succinate Tablet, Film Coated, Extended Release
Product Images NDC 68180-593

The figure 4 shows the estimated proportion of relapses versus the number of days following randomization in study 5. The x-axis represents the time to relapse in days from randomization while the y-axis represents the estimated proportion of patients. The blue line represents patients treated with Desvenlafaxine extended-release tablets 50mq while the orange line represents patients treated with placebo. The percentage of relapse is also provided on the y-axis.*

This appears to be a graph or chart showing the estimated proportion of patients with relapse over time (measured in days from randomization) for both Desvenlafaxine extended-release tablets and Placebo. Without more context or information, it is difficult to provide a more detailed description or interpretation of the information presented.*

This is a medication containing Desvenlafaxine extended-release tablets used for treating depression. Each tablet contains 38mg of Desvenlafaxine succinate monohydrate, equivalent to 25mg of Desvenlafaxine. The usual dosage has been provided in the prescribing information while the medication is to be stored at 20°to 25°C. Lupin Pharmaceuticals, Inc is the manufacturer of the medicine, while Lupin Limited 2 is the manufacturer of tablets. The medication is not to be crushed, cut, chew, or dissolved before swallowing. It comes in packages with 30 tablets, and the pharmacist should dispense medication guides to each patient. A URL has been provided for the medication guide: www.lupin.com/desvenlafaxineertab-mg.pdf.*

Desvenlafaxine Extended-Release Tablets is a medication with NDC 68180-592-06 that is dispensed in a unit of use of 30 tablets. Each extended-release tablet contains 76 mg of desvenlataxine succinate monohydrate, which is equal to 50 mg of desvenlafaxine. It is essential to dispense the medication guide to each patient. The medication guide is available at "Wiwklupin.com/desvenlafaxineertab-mg.pdi" or by scanning the OR code. The manufacturer is Lupin Limited in Goa 403 722 INDIA, and the drug is manufactured for Lupin Pharmaceuticals, Inc. It's usually not recommended to crush, cut, chew, or dissolve the tablet, and should be stored between 20° to 25°C (68° to 77°F). The usual dosage should be accompanied by prescribing information. The package is meant to be dispensed as a unit. The code number of the drug is No. GO/DRUGS/654.*

This is a medication information for a Desvenlafaxine succinate monohydrate extended-release tablet containing 152 mg of the drug. It is equivalent to a 100mg dose. The package should be dispensed as a unit, and each tablet should not be crushed, chewed, or dissolved. The manufacturer of the drug is Lupin Limited based in Goa, India. The recommended dosage is specified on the package, and a medication guide should be dispensed to each patient by the pharmacist.*

This is a figure showing the effect of other drugs on Desvenlafaxine pharmacokinetics. The drugs tested were CYP3A4 inhibitors such as Ketoconazole. The graph shows the geometric mean ratio (90% CI) values for Gmex and AUC-1.43 (1.38-1.49) with a reference range of 0-20. It is not possible to determine what the graph is measuring without additional information.*

Figure 3 shows the effects of Desvenlafaxine on the pharmacokinetics of other drugs. The table presents the change due to the interacting drug K 'Geometric mean ratio (90% CI)' for different doses of Desvenlafaxine compared to the reference drug. The interacting drugs listed are Desipramine, Midazolam, Tamoxifen, and Aripiprazole. The results for Tamoxifen's active metabolite 4-hydroxy-tamoxifen, Tamoxifen's active metabolite Endroxifen, and Aripiprazole's active metabolite dehydro-aripiprazole are also presented.*